Immunomodulator effect of topical zinc oxide application in tuberculin skin test

Cagatay Nuhoglu,1 Evrim Hepkaya,1 Zehra Esra Onal,1 Narin Akici,1 Tamay Gurbuz,1 Vildan Atasayan,1 Omer Ceran2

1Department of Pediatrics, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
2Department of Pediatrics, Istanbul Medipol University Faculty of Medicine, Istanbul, Turkey

ABSTRACT

OBJECTIVE: We aimed to evaluate the sensitivity of tuberculin skin test (purified protein derivative-PPD) by topical zinc application on test site to improve diagnostic reliability.

METHODS: We performed this study in 100 children aged 6–14 years, and plasma zinc levels were analyzed after 10–12 hours fasting. After PPD, we applied 40% zinc oxide cream on one forearm and placebo on the other forearm. PPD indurations were measured 72 hours later.

RESULTS: In this study, 26% of the children showed increases in PPD induration following local zinc applications. There was no correlation between indurations size and serum zinc levels.

CONCLUSION: We concluded that topical zinc cream application can enhance sensitivity of tuberculin reactivity in the diagnosis of tuberculosis.

Keywords: Purified protein derivative; tuberculin skin test; zinc.

Tuberculosis, is a serious illness in developing countries, particularly in asymptomatic, immunosuppressed children. It is estimated annual risk of tuberculosis infection in children in developing countries is 2–5% [1]. The estimated risk of developing tuberculosis diseases for a young child infected with mycobacterium tuberculosis as indicated by positive tuberculin test is approximately 10% [2]. Nearly 8–20% of the deaths caused by tuberculosis occur in children [3]. We can diagnose the latent infection by means of tuberculin skin test (purified protein derivative-PPD). However, the reliability of this test is limited by false-negative results, particularly in children who have poor nutritional status. Deficiency of zinc, a micronutrient that modulates immune response and supports antibacterial immunity, can cause false-negative results in PPD skin test [4-6]. Therefore, we investigated whether the application of topical zinc application would enhance the sensitivity of PPD for the diagnosis of the disease.

MATERIALS AND METHODS

This study was performed in 100 children aged 3–14 years (mean age, 8.98±2.75 years) and hospitalized in Haydarpaşa Numune Training and Research Hospital Pediatric Department. After receiving ethical approval and informed written consent, venous blood of the children after 10–12 hours fasting were collected. Plasma
zinc levels were analyzed using atomic absorption spectroscopy. The patients who had severe infections that could affect immune system anergic viral infections, steroid administration, and immune suppressive status were excluded.

PPD was performed and evaluated by the same doctor during the study. The doctor injected 0.1 ml tuberculin (5U in 0.1 ml Aventis-Pasteur) in the volar surfaces of both the forearms. After implementations, he covered skin-test side on the left arm with zinc oxide dissolved in aqueous cream of 40% elemental zinc, whereas he covered skin-test sides on the right arm with 1 ml of placebo creams. Both creams had the same color and odor and were provided in a similar looking cup. After 72 hours, he measured the sizes of indurations in both arms by “ball-point-pen.”

Number Cruncher Statistical System (NCSS) 2007 and PASS (Power Analysis and Sample Size) 2008 Statistical Software (Utah, USA) were used. While evaluating the data of the study, we used defining statistical methods such as mean value, standard deviation, median, and rate. We performed student’s t test order to demonstrate serum zinc levels according to genders. We used Mann–Whitney U test and Wilcoxon Signed Rank test in evaluating PPD indurations with placebo and zinc supplementation. For evaluating the associations of the parameters with each other, we used Spearman’s correlation analysis. Statistical significance was accepted as p<0.05.

RESULTS

This study included 41% males and 59% females in a total of 100 children (mean age, 8.98±2.75 years). All patients had scars. The mean serum zinc level in females was 89.86 mcg/dl, while it was 90.15 mcg/dl in males. Serum zinc levels of 12 patients was lower than normal (<70 mcg/dl). The mean serum zinc levels of the children were 89.98±24.61 mcg/dl. There was no significant correlation among plasma zinc levels between the PPD induration sizes with placebo and with zinc application (r=0.139; p=0.167). The mean age of the children was 8.98±2.75 (min: 3, max: 14) years. When the mean PPD indurations size of the children with placebo ointment was 2.53±4.44 (min: 0, max: 20) the mean PPD indurations size with zinc application was 3.55±5.67 (min 0, max: 20) mm (p=0.001). The mean PPD indurations size with zinc application was significantly higher than that with placebo (p<0.001) (Table 1).

Seventy six percent induration of the responses to PPD with placebo cream were smaller than 5 mm, while 22% were 6–14 mm and 2% were larger than 15 mm. Induration responses to PPD with zinc ointment were as follows: 71% were smaller than 5 mm, 21% were 6–14 mm, and 8% were larger than 15 mm (Fig. 1).

Of 100 children, 74 of did not show induration with placebo or zinc cream application following PPD. Topical zinc cream application did not have an effect in non-reactive tuberculin test. The remaining 26 children had indurations larger than 0 mm. In this study, 26 of the patients showed increases in PPD indurations, following local zinc application. When 5 of them had a negative PPD response in the placebo sites, PPD response was evaluated as suspiciously positive following topical zinc application. When 6 of them had indurations of 6–14 mm in the placebo cream sites, they were measured as positive (>15 mm) in the local zinc cream sites. Of 26 patients, 11 had significantly higher PPD induration sizes on zinc cream sites than placebo cream sites.
ing zinc creams modulated response of PPD by increasing induration sizes (Fig. 2).

**DISCUSSION**

Zinc is essential for normal development and function of cell-mediated immunity, neutrophils, and natural killer (NK) cells. It is needed for DNA synthesis, RNA transcription, cell division, and cell activation. Zinc deficiency adversely affects the secretion and functions of cytokines, which are the basic messengers of the immune system. Zinc is involved in maturation and differentiation of T cells. The gene expression of interleukin (IL)-2 and interferon (IFN)-γ are zinc dependent. IL-2 is involved in the activation of NK and T cytolytic cells. IFN-γ and IL-12 together play a major role in killing of parasites, viruses, and bacteria by macrophages–monocytes. Zinc deficiency is associated with impaired phagocyte function, lymphocyte depletion, decreased immunoglobulin production, reduced T4/T8 ratio, and decreased IL-2 production. Severe zinc deficiency is characterized by severely depressed immune function, frequent infections, bullous pustular dermatitis, diarrhea, and alopecia. Zinc circulates at a concentration of 70–120 mcg/dl, with 60% percent bound to albumin and 30% tightly bound to macroglobulin [7-13].

Low plasma zinc is usually defined as a value less than 60 mcg/dl. Some investigators argue that plasma zinc measurements are relatively insensitive and that zinc levels in neutrophils and lymphocytes may be more sensitive. The criteria for zinc deficiency is the decreased zinc level either in lymphocytes (≤50 mcg/10 cells) or in granulocytes (≤42 mcg/10 cells) [14, 15].

Rao et al. performed a study on 50 volunteer healthy adults. They evaluated serum zinc levels. They placed PPD at the proximal sides of the palmar forearms and placed Candida antigens at distal sides of the forearms. They placed placebo cream in one forearm and zinc cream in the other one. The indurations sizes were measured in 24, 48, and 72 hours. The induration size of PPD was larger than 32% percentage of the zinc cream applied arm. Topical zinc caused greater tuberculin skin test augmentation in zinc deficient subjects. Zinc cream had no effect on subjects with normal zinc levels. Skin tests with zinc applications were significantly more likely to have positive results than the contra lateral control skin tests with placebo cream application (94% zinc, 76% placebo) [16]. The main difference of this study from ours was statistically significant difference in PPD responses of patients with lower zinc levels; however, there was no difference in the patients within normal serum zinc levels. In our study, there was a significant difference in PPD induration sizes after local zinc application independently plasma zinc levels. The similarity of our study with this one was the evaluation of immunomodulatory effect of using local zinc application to enhance PPD response.

Kwok et al. investigated the effect of topical zinc application to increase the sensitivity of PPD. Of 58 elderly patients, 38 (66%) had negative reactions with placebo ointment. Of these negative responders, 14 (37%) showed positive reactions with topical zinc ointment, 12 (32%) had weakly positive reactions, and 12 (32%) remained negative. They determined that 37% of patients with negative PPD had reacted as positive after applying zinc cream ointment. There was no significant difference in the plasma zinc levels between the different grades of topical zinc effect in the negative responders [17]. Although this study was different because it included elderly people, it supported the findings of our study because it had shown that topical zinc application modulated the immune response.

Cuevas et al. investigated the differences of positive PPD responsiveness in patients younger than 15 years old. PPD was performed in patients at an interval of 2 years. The group receiving oral zinc application before applying the test showed increase in positive responsiveness and indurations measurements compared with the placebo group [18]. In this study patients were given oral zinc supplements but, our patients were given topical zinc application, differently from the previous study. However, the findings of both studies supported each other because they revealed that zinc modulates the cell-
mediated immune responsiveness.

Castillo-Duran et al. evaluated the immunity and development after adding zinc application in 32 marasmic infants. Half of the subjects were given 2 mg/kg oral zinc during 3 months, and the other half were given placebo. They evaluated PPD responses in the first and 90th day. Before applying zinc, 33% of the patients showed positive PPD results. After zinc application, 67% of the patients showed positive PPD results. There was no significant difference of PPD responsiveness in placebo group [19]. This study supported the immunomodulatory effect of the zinc application for enhancing the PPD reactivity.

Kramer TR et al. investigated T lymphocyte proliferation in 140 children aged 6–13 years by evaluating the PPD responsiveness after oral zinc application with 25 mg/day during 6 months. The group receiving zinc application showed significant increase in PPD responsiveness compared with the one receiving placebo [20]. This study differed from ours by systemic use of zinc combined with vitamin A in a longer duration. However, it also supported our findings that zinc application increased the immunomodulatory effect.

Although PPD plays a major role in the diagnosis of latent tuberculosis, nutritional status, immunity, chronic illness of the patients, and environmental factors can decrease its sensitivity. The incidence of tuberculosis increases not only in adulthood but also in childhood. As a result, the effect of zinc on PPD responsiveness gains more importance in diagnostic approach. Although systemic use of zinc application had been preferred in the previous studies, we aimed to benefit from local zinc cream application providing simple and inexpensive effect on enhancing the sensitivity of PPD for the diagnosis of the diseases.

We believe that future studies including more subjects can support the sensitivity of PPD responses in the cases with lower plasma zinc levels following topical zinc applications. We recommend using local zinc ointments without screening plasma zinc levels after performing PPD, to enhance the sensitivity of the test so that we can decrease the false-negative results. If we use the booster effect of topical zinc after performing PPD, we can enhance tuberculin reactivity, causing optimal diagnostic approach.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. Chugh S. Paediatric tuberculosis and DOTS strategy under RNTCP. J Indian Med Assoc 2008;106:799–802.
2. Enarson DA. The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes. Tuber Lung Dis 1995;76:95–9.
3. Comstock GW, Livesay VT, Woolpert SE: The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131–8.
4. Golden MH, Harland PS, Golden BE, Jackson AA. Zinc and immunocompetence in protein-energy malnutrition. Lancet 1978;1:1226–8.
5. Lin RY, Busher J, Bogden GJ, Schwartz RA. Topical zinc sulfate augmentation of human delayed type skin test response. Acta Derm Venereol 1985:65:190–3.
6. Karyadi E, West CE, Shultzink W, Nelnau RH, Gross R, Amin Z, et al. A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. Am J Clin Nutr 2002;75:720–7.
7. Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr 1998;68:447S–63S.
8. Prasad AS. Zinc Deficiency. In: Trace Element in Human Disease. 1995;573–86.
9. Prasad AS. Diagnostic approaches to Trace Element Deficiencies. In: Chandra RK, editor. Trace Elements in Nutrition of Children. New York: 1995. p. 17–40.
10. Prasad AS. Zinc in growth and development and spectrum of human zinc deficiency. J Am Coll Nutr 1988;7:377–84.
11. Prasad AS. Clinical, immunological, anti-inflammatory and antioxidiant roles of zinc. Exp Gerontol 2008;43:370–7.
12. Overbeck S, Rink L, Haase H. Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases. Arch Immunol Ther Exp (Warsz) 2008;56:15–30.
13. Fraker PJ, Haas SM, Luecke RW. Effect of zinc deficiency on the immune response of the young adult A/J mouse. J Nutr 1977;107:1889–95.
14. Hambidge KM, Casey CE, Krebs NF. In: Merz W, editor. Trace elements in human and animal nutrition. Orlando: Academic Press; 1986. p. 1.
15. Wood RJ. Assessment of marginal zinc status in humans. J Nutr 2000;130:1350S–4S.
16. Rao VB, Pelly TF, Gilman RH, Cabreva L, Delgado J, Soto G, et al. Zinc cream and reliability of tuberculin skin testing. Emerg Infect Dis 2007;13:1101–4.
17. Kwok T, Fatherby MD, Cookson J, Potter JF, Castleden CM. Can topical zinc accentuate tuberculin reactivity in the elderly? Respir Med 1994;88:47–8.
18. Cuevas LE, Almeida LM, Mazunder P, Paixão Ac, Silva AM, Maciel L, et al. Effect of zinc on the tuberculin response of children exposed to adults with smear-positive tuberculosis. Ann Trop Paediatr 2002;22:313–9.
19. Castillo-Duran C, Heresi G, Fishberg M, Uauy R. Controlled trial of zinc supplementation during recovery from malnutrition: effects on growth and immune function. Am J Clin Nutr 1987;45:602–8.
20. Kramer TR, Udomkesmalee E, Dhanamitta S, Sirisinha S, Charoenkiartkul S, Tuntipopipat S, et al. Lymphocyte responsiveness of children supplemented with vitamin A and zinc. Am J Clin Nutr 1993;58:566–70.

Authorship contributions: Concept – C.N.; Design – C.N.; Supervision – C.N.; Materials – E.H., N.A.; Data collection &/or processing – E.H., V.A.; Analysis and/or interpretation – C.N., Z.E.O., T.G.; Writing – C.N., Z.E.O., T.G.; Critical review – C.N., O.C.